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Abstract33
We describe the population pharmacokinetics of an acepromazine (ACP) metabolite (2-(1-34
hydroxyethyl)promazine) (HEPS) in horses for the estimation of likely detection times in35
plasma and urine. Acepromazine (30 mg) was administered to 12 horses, and blood and urine36
samples were taken at frequent intervals for chemical analysis. A Bayesian hierarchical model37
was fitted to describe concentration-time data and cumulative urine amounts for HEPS. The38
metabolite HEPS was modelled separately from the parent ACP as the half-life of the parent39
was considerably less than that of the metabolite. The clearance (Cl/FPM ) and volume of40
distribution (V/FPM ), scaled by the fraction of parent converted to metabolite, were estimated41
as 769 L/h and 6874 L, respectively. For a typical horse in the study, after receiving 30 mg42
of ACP, the upper limit of the detection time was 35 hours in plasma and 100 hours in43
urine, assuming an arbitrary limit of detection of 1 µg/L, and a small (≈ 0.01) probability44
of detection. The model derived allowed the probability of detection to be estimated at the45
population level. This analysis was conducted on data collected from only 12 horses, but we46
assume that this is representative of the wider population.47
Keywords: Bayesian modelling; Detection times; Dope-testing; Equine; Pharmacoki-48
netics49
50
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1 Introduction51
Acepromazine (ACP) is a phenothiazine tranquilizer commonly used in horses to re-52
duce stress during transportation and also to calm excitable horses during veterinary53
procedures or in training (Smith et al., 1996). As with most therapeutic substances,54
ACP is prohibited in competition by most racing organizations (Chou et al., 2002). If55
a sufficiently long wash out period is not observed before a race after ACP has been56
administered, the trainer runs the risk of detection and associated penalties.57
Drug screening is regulated by racing authorities who are in the process of establishing58
limits of detection in blood and urine for a range of therapeutic substances, based59
either on the parent drugs or their metabolites. These limits are being established in60
order to protect the integrity of the sport without adversely affecting the welfare of the61
horse by restricting legitimate therapeutic treatment, as discussed by Toutain (2010).62
Therefore, there is interest in assembling detailed pharmacokinetic data to enable the63
rational setting of analytical detection limits and corresponding withdrawal times for64
particular prohibited substances.65
Approaches to the detection of prohibited substances in horse racing differ from coun-66
try to country, such that estimated withholding times may vary depending upon which67
country the horse is racing in. For example, urine samples are favoured for drug de-68
tection in Australia, whereas plasma samples are preferred in the USA. Nevertheless,69
both countries consider a drug test to be positive if the parent compound or one of70
its metabolites are detected on race day. Therefore, to provide precise estimates of71
withholding times, an understanding of the metabolism and the renal excretion of the72
drug is required. This understanding can be facilitated through the modelling of the73
pharmacokinetics (PK) of the drug, that is, what the body does to the drug after admin-74
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istration (Benet, 1984). In general, such models describe how the drug is metabolized75
and then eliminated from the body over time.76
In this paper, we consider ACP as the parent drug and 2-(1-hydroxyethyl)promazine77
(HEPS) as the principle metabolite. This leads to the consideration of a parent-78
metabolite model which describes the conversion of ACP to HEPS, and the elimination79
of both substances from the body via the urine. The individual (or horse) specific80
PK for ACP have been studied previously (Ballard et al., 1982; Hashem and Keller,81
1993; Marroum et al., 1994). To our knowledge, limited research has appeared in the82
literature in regard to the PK of HEPS, see Schneiders et al. (2012), who suggest that83
detection of HEPS could be used as an indicator for the use of ACP. Furthermore,84
detection times are often reported in studies of a few (3 to 6) horses and in absolute85
terms (that is, number of hours or days) with no probability values attached to them.86
In the present study, we sought to determine more accurate detection times by using87
a larger number of horses (12) and to explore a means to judge, not just the time of88
detection, but the probability of detection at a given time.89
We developed an understanding of the PK and renal excretion of HEPS at a population90
level through the implementation of a Bayesian hierarchical model (BHM). Covariates91
were available and included breed, body weight (kg) and age (years), and these were92
explored as potential effects to minimize unexplained between subject variability. Also,93
plasma concentrations were subject to measurement error as two measurements were94
taken for each sample, and analyzed separately. Given the two approaches to measure95
plasma concentration from each sample generally gave differing results, this source96
of variability needed to be considered in the model. Once a parsimonious statistical97
model had been developed, simulation techniques were used to estimate detection times98
in plasma and urine.99
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2 Analytical methods100
ACP and HEPS were analysed by LC-MS following extraction from blood plasma and101
urine using a solid-phase extraction method. To prepare the samples for analysis,102
aliquots were spiked with internal standards (propionylpromazine hydrochloride and103
HEPS-d4 maleate), then diluted with either acetic acid (urine), or acetic acid plus104
methanol (plasma).105
The samples were centrifuged to remove proteinaceous material before the supernatant106
fractions were loaded onto IST Isolute HCX solid phase extraction cartridges which107
had previously been conditioned with methanol and acetic acid. The cartridges were108
washed with acetic acid and methanol, dried briefly and then eluted with an mixture109
of ethyl acetate, methanol and ammonium hydroxide. The eluates were evaporated110
to dryness at 60C under a stream of nitrogen, and reconstituted in isopropanol and111
ammonium acetate (20 mM) for analysis.112
The samples were analysed using a Waters Acquity UPLC system equipped with a113
Waters Acquity UPLC BEH C18 analytical column and a Phenomenex Security-Guard114
C18 guard column interfaced to an Applied Biosystems 4000 Q-Trap mass spectrometer.115
The mobile phase varied from 100% aqueous ammonium acetate to 40% ammonium116
acetate: 60% acetonitrile, which was run as a gradient. The instrument was operated117
in positive ion atmospheric pressure chemical ionisation (APCI) mode with ion source118
conditions optimised for acepromazine.119
Calibration standards and quality control samples were prepared by spiking pooled120
blank equine plasma and urine with acepromazine maleate and HEPS maleate. The121
specificity of the method was assessed by analysing 12 blank equine plasma and 12122
blank equine urine samples. No significant matrix interference was observed and the123
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calibration curves for both acepromazine and HEPS in plasma and urine were linear124
over the full calibration ranges. Correlation coefficients for acepromazine were 0.9889125
or greater and for HEPS 0.9996 or greater in both matrices. The limit of quantification126
(LOQ) for both analytes in both matrices was 1 ng/mL. The limit of detection (LOD)127
based on a signal to noise ratio greater than 3 was less than 1 ng/mL in all cases.128
Accuracy and precision data were collated from the quality control samples prepared at129
low and high concentrations. The accuracy of detection (% of nominal) for acepromazine130
in plasma ranged from 95% to 109%, with a precision (% CV) of 3.6 to 5.3%. In urine,131
values for accuracy and precision for acepromazine detection were 89% to 104%, and132
4.4% to 7.7%, respectively. The corresponding values for HEPS were: accuracy 88 to133
104%, precision 6.4 to 7.9% (plasma); and accuracy 103% to 119%, precision 3.1% to134
4.5% (urine).135
3 Design and data collection136
Data were collected on twelve horses (geldings) after an intravenous administration of137
acepromazine maleate equivalent to 30 mg dose of ACP, denoted as D. Injections were138
given into the jugular vein after the insertion of an indwelling catheter on the morning139
of the experiment. A summary of the 12 horses is given in Table 1. All horses were140
weighed the day before drug administration and at the end of the study, and it was141
found that the weight of each horse had changed slightly over the duration of the study,142
despite being fed a diet that was designed to maintain a stable body weight. If this143
change was linear (this is the only change we can estimate given these data), then there144
was less than a 6% change in weight across all horses. Hence, weight as a time varying145
covariate was not considered due to such small changes, and the average (or median)146
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of the two measurements was used for covariate exploration.147
ACP and HEPS concentration-time data were derived from the chemical analysis (as148
discussed in the previous section) of blood and urine samples collected at frequent149
intervals. 10 mL blood samples were collected into lithium heparin vacutainers at the150
following time points: 0.08, 0.17, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 hours151
after administration. Urine samples were collected approximately 2, 4, 6, 8, 12, 24, 36152
and 48 hours after administration. The horses were trained to urinate to a whistle.153
The urine was collected into a 2L plastic container that was attached to each horse.154
Each horse also wore a specially designed harness known as a ’horse nappy’ between155
collection times to ensure all urine was collected. The midpoint between collection times156
was used as the average urine amount. Hence, the average urine amount was modelled157
over each of the time spans. Parent ACP was not detected in urine and, hence, could158
not be modelled. All samples were refrigerated directly after collection, and stored at159
-20C until analyzed.160
4 Model161
Realistic statistical models for PK data are often complex systems incorporating auxil-162
iary variables in hierarchies or strata. Bayesian statistical methodology provides power-163
ful methods for modelling such data, combining prior knowledge with information from164
the data to yield a posterior distribution from which all inference about unknowns can165
be made. Unfortunately, sampling from this posterior distribution can be difficult in166
practice as no closed form solution may be available. This led to the development of a167
collection of proven computational methods used across a wide area of applied sciences168
and technology. The most widely used computational method is Markov chain Monte169
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Carlo (MCMC), a technique that can be used to sample from a target distribution170
(here, a posterior) that is difficult to sample from directly. This facilitates posterior171
inference in complex settings.172
A full conditional hierarchical Bayesian analysis was undertaken using WinBUGS (Lunn173
et al., 2000) where MCMC techniques are used to sample from the posterior distribution174
of estimable parameters. Reviews of Bayesian modelling of pharmacokinetic data are175
given by Duffull et al. (2005) and Lunn et al. (2002), and an example is given by176
Dansirikul et al. (2005).177
In our analysis, two MCMC chains were run simultaneously, each with different ini-178
tial parameter estimates for each parameter. Convergence of the MCMC chains to the179
stationary distributions were assessed in two ways. Firstly, the Gelman and Rubin180
convergence diagnostic (Kass et al., 1998) was calculated for each parameter. This181
diagnostic essentially compares the between chain variability to the within chain vari-182
ability. If this variability is similar, the value of the diagnostic will be close to 1. In183
our analysis, if values were less than 1.1 for all parameters, then it was assumed that184
the stationary distribution had been reached under this diagnostic. As a further check,185
the trace history for each parameter was plotted to ensure the ‘fuzzy caterpillar’ was186
observed (Lunn et al., 1999).187
The two MCMC chains were run for 20,000 samples with the first 10,000 being discarded188
as a ‘burn-in’. If the above convergence criteria were met, the two chains were pooled189
to provide samples from the stationary/posterior distribution. It is this distribution190
upon which all inferences were drawn.191
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4.1 Parent and metabolite model192
The full dataset consisted of ACP and HEPS plasma concentrations and urine amounts193
over time. Therefore, a multivariate response model needed to be derived. A full194
parent-metabolite model based on mass balance is given in Figure 1.195
Figure 1 shows a five compartment parent-metabolite model. Initially, the parent (P )196
enters into the first of two compartments, where it can move between this compartment197
(P1) and another (P2). A two compartment model was proposed for this part of the198
model as this was fitted in the analysis of ACP given by Ballard et al. (1982), Hashem199
and Keller (1993) and Marroum et al. (1994). A fraction of the parent is either converted200
to the metabolite (FPM), excreted renally (FEP ) or eliminated non-renally (1−FPM −201
FEP ). In the second case, the triangle represents the bladder (P3), and the parent will202
continue to accumulate here until the horse empties the bladder. For the fraction of203
the parent that is converted to the metabolite (M), a fraction of M is either excreted204
renally (FEM) or non-renally (1− FEM). In this first case, the metabolite accumulates205
in the bladder (M2, represented by a triangle) until the horse empties the bladder. The206
ks denote rate constants for movement between compartments.207
A simplification of this parent metabolite model was made. Given the half-life of the208
parent was considerably shorter than that of the metabolite, we can conclude that the209
kinetics of the metabolite were not being driven by the parent. In such cases, it should210
be sufficient to model the metabolite alone, particularly given we are only interested211
in estimating detection times for the metabolite. Notably, this is a key assumption in212
our approach, and further research would be required to determine if this biased our213
analysis.214
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4.2 Metabolite model215
Figure 2 shows the proposed model for plasma concentration and cumulative urine216
amount for the metabolite only. Initially, ACP appears in compartment P1 and is217
converted to HEPS which appears in M1 (the molecular weights of ACP and HEPS are218
326 and 345, respectively). Here, M1 represents the amount of HEPS in plasma, with a219
fraction being excreted renally (FE) to the bladder (M2), and a fraction excreted non-220
renally (1 − FE). The metabolite will then accumulate in M2 until the horse empties221
their bladder.222
From Figure 2, the following is true223
k22 =
FECl
V
k23 =
(1− FE)Cl
V
FE =
∫
∞
0
k22M1dt
D
,
where ClR = FECl and ClNR = (1−FE)Cl are renal clearance and non-renal clearance,224
respectively; Cl = ClR + ClNR and V is the volume of distribution.225
Since we only model HEPS, estimates of clearance and volume of distribution are scaled226
by the fraction of the parent converted to the metabolite, that is, Cl/FPM and V/FPM .227
To facilitate the estimation of the parameters in the model, the assumption is that228
FPM = 1. We note, however, that Ballard et al. (1982) show that approximately229
50% of injected ACP binds to red blood cells. Of this 50%, an estimated fraction230
of 0.99 (±0.01) is converted to HEPS, see Schneiders et al. (2012). Even though our231
10
parameterization may not reflect the true biological process, it does allow an accurate232
mathematical representation of the data, see Duffull et al. (2000).233
The ordinary differential equations (ODEs) that describe the kinetics of this model for234
the amount of the metabolite are as follows. We note that these are linear ODEs, and235
hence can be solved analytically.236
dP1
dt
= −k12P1
dM1
dt
= k12P1 − k22M1 − k23M1
dM2
dt
= k22M1,
where P1(0) = D,M1(0) = 0,M2(0) = 0.237
The above ODEs provide the structural model for the analysis. When solved, they238
provide predicted responses for each of the three compartments. For modelling the239
metabolite data, we are only interested in the solution to compartments M1 and M2.240
Denote the predicted responses in each of these compartments as f1(.) and f2(.), re-241
spectively.242
The following describes the full probabilistic model. In model development, we consider243
a number of alternative models in an attempt to derive a parsimonious description the244
multivariate data. Instead of describing all models considered, we describe a ‘full’ model245
such that all other rival models are parametrically nested within this full model.246
The hierarchical structure of the probabilistic model can be described in the following247
stages:248
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Stage 1:249
yijkl|λij, γijkl ∼ N(fijkl, γijkl), (1)
where λij = (Clij, FEij, Vij)
′, fijkl = fl(λij, k12, tijkl, D) represents the model prediction250
for the kth response on the jth measurement type on the ith individual in compartment251
Ml, and the variance of this response is given by γijkl = σ
2
add,l + σ
2
prop,lf(λij, tijkl, D)
2
252
for i = 1, . . . , N (the total number of horses), j = 1, 2 (the two sources for the chemical253
analysis), k = 1, . . . , nijl (the total number of observations from Ml on individual i on254
measurement type j) and l = 1, 2.255
Stage 2:256
logλij| log θi,Φ ∼MVN(log θi,Φ), (2)
where θi = (Cli, FEi, Vi)
′ represents the ith individual’s mean PK behavior and Φ is257
the measurement error variance-covariance matrix of PK parameters.258
Stage 3:259
log θi| logµ,Zi,Ω ∼MVN(logµ,Ω), (3)
where Zi represents the covariate values for the ith individual, Ω the between horse260
variability and µ = (Cl, FE, V )
′ the population PK parameters.261
Stage 4 (priors):262
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σ2add,l ∼ Uni(0, 100)
σ2prop,l ∼ Uni(0, 100)
log(Cl, V )′ ∼ MVN(0, 1000× I)
k12 ∼ HN(0, 1000)
logFE ∼ Uni(−300, 0)
Φ ∼ W (0.001× I, 5)
Ω ∼ W (0.001× I, 5),
where l = 1, 2, and Uni(), MVN , HN and W denote the Uniform, Multivariate Nor-263
mal, half-Normal and Wishart distributions, respectively. These priors were chosen to264
be essentially uninformative meaning that they should have minimal influence in de-265
termining the parameter estimates when compared to the observed data. Note that,266
when estimating FE, it is possible (through between subject variability (BSV) and267
measurement error variability (MEV)) that this estimate may be larger than 1. This268
is impossible in practice, so the constraint min{1, FE} was imposed in the estimation.269
As can be seen, k12 was assumed to be a fixed effects parameter, so no BSV (or MEV)270
was estimated.271
5 Results272
The observed (log) concentration-time data and accumulated urine amounts of HEPS273
for the 12 horses are shown in Figure 3. The demographic data collected for the 12274
horses was breed, weight (kg) and age (years). Of the 12 horses, 4 were thoroughbreds275
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and 8 were standardbreds. The mean (± SD) body weight of all horses was 544 (± 48)276
kg and the mean (± SD) age was 8 (± 2.8) years.277
5.1 Structural and residual error model278
The model specified in Figure 2 was considered with additive, proportional and a mix-279
ture of additive and proportional residual errors on each of the two responses. These280
model fits can be compared by considering deviance, calculated as minus twice the log-281
likelihood. Given we typically wish to select parameter estimates that maximize the282
log-likelihood, we would like to select the model with the smallest deviance. However,283
as more parameters are included, the model will generally fit the data ‘better’ and will284
therefore result in a smaller deviance (even though this decrease may not be statisti-285
cally significant). Therefore, we would ideally like to select the model that has small286
deviance and a small number of parameters.287
The results of model fits are summarized in Table 2. The smallest median deviance288
can be seen for the model that has a proportional residual error term on plasma con-289
centrations and an additive residual error on the cumulative urine amounts. Further,290
this model has less than or equal the number of parameters to estimate when compared291
with other rival models. Therefore, this residual error structure was assumed for further292
analysis.293
5.2 Measurement variability294
Plasma concentrations for each horse were chemically analyzed in duplicate at each295
time point. We therefore explored if significant measurement error existed in the data.296
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Measurement variability was accounted for by including a random effect on each indi-297
vidual parameter (is that, Cli, FEi and Vi). Table 2 shows the median deviance values298
for models fitted with and without MEV. As can be seen, there was a reduction in299
the median deviance when MEV was included. However, it is unclear whether this is300
significant given the extra number of estimable parameters introduced into the model.301
Hence, the deviance information criterion (DIC) was used to compare the two models302
(Spiegelhalter et al., 2002). The information criterion is as follows.303
DIC = pD + D¯,
where pD = D¯−D(θ¯) is the effective number of parameters in the model, D¯ = Eθ[D(θ)]304
and θ¯ is the expectation of θ.305
From the above formula, the DIC penalizes large values of both D¯ and pD such that the306
model with the smallest DIC value is preferred. For the model with MEV, D¯ = 1978.26,307
D(θ¯) = 1915.280, pD = 62.981 and DIC = 2041.240, compared with D¯ = 2048.94,308
D(θ¯) = 2012.48 , pD = 36.457 and DIC = 2085.390 for the model without MEV. The309
results show that the model with MEV gave the smallest DIC value, and hence this310
model was retained for further investigation.311
5.3 Covariate modelling312
Covariate relationships were initially investigated through the use of scatter plots against313
individual parameters. If any of the relationships warranted further investigation, then314
models with these covariate relationships were fitted. Limited data were available, so315
results from this part of the analysis should be treated with caution.316
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The covariate plots can be seen for HEPS in Figure 4. There did not appear to be a317
relationship between any covariates and the estimates of individual parameters except318
for log Vi and median horse weight (Figure 4c). That is, it appeared that as the horse319
weight increased, log Vi also increased. The plot also suggests that the relationship (if320
it exists) could be linear. As such, the (median) weight of each horse was included in321
the model as follows:322
log βi = β1 + β2
(
wi
548
)
,
where wi is the weight of the ith horse, and 548 is the median weight over all horses.323
The results from the fit where weight was included as a covariate on log V are given in324
Table 2. As can be seen, there was no reduction in the median deviance of the model325
with weight, compared to the model without weight. However, this is not the full326
picture as it is possible for a covariate to be significant without there being a significant327
reduction in deviance. Therefore, we explored other indicators such as whether the328
BSV on log V had been reduced, and also if the credible interval for β2 (from above)329
included zero or not.330
The posterior distribution of β2 was examined and it was found that zero was a highly331
probable value. Further, the BSV of log V without weight in the model was 0.0729,332
while with weight, this reduced to 0.0709; reduction of about 3%. Given this, it was333
concluded that weight was not significant, and therefore it was not included into the334
final model.335
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5.4 Model fit336
The individual fits to the data can be seen for plasma concentrations in Figure 5 and337
cumulative urine amounts in Figure 6. The individual fits for plasma concentrations are338
represented by two lines corresponding to duplicate measurements made on each blood339
sample as the MEV was found to be significant. In some horses, this is difficult to see,340
but is particularly visible for horses 4 and 5. All individual specific models seemed to341
fit the data well. The same was true for the individual cumulative urine fits.342
A summary of parameter estimates (posterior medians) for the final model is given343
in Table 3. The large estimate of k12 shows a rapid rate of conversion from ACP to344
HEPS. The clearance rate of HEPS was 769 L/hr with a volume of distribution of 6874345
L (both scaled by the fraction of parent converted to metabolite). The BSV of Cl, FE346
and V are small, at around 30%. No estimate for the BSV of k12 is given as this was347
considered as a fixed effect in the model.348
5.5 Model checking and validation349
Figure 7 shows the residual error plots for the final model. The standardized residuals350
are given for both responses. For plasma concentrations, all plots appear reasonable351
given the assumption of Normally distributed residuals. The QQ-plot shows discrepancy352
between the standardized residuals and the fitted Normal density at the lower tail, but353
this was not deemed significant. Similarly, the residual plots for cumulative urine354
amounts generally do not violate the assumption for Normality. Again, discrepancies355
appear in the QQ-plot, but at both tails.356
Posterior predictive checks were used to determine whether the model developed was357
17
consistent with the data. The checks were performed in the following way. After358
fitting the final model, each parameter has a posterior distribution. This distribution359
summarizes the uncertainty about the estimate (given the prior and the observed data).360
Ten thousand random samples were drawn from the posterior distribution, and the361
concentration (µg/L) at time t hours was simulated (based on each of the 10,000 random362
samples). This produced a distribution of concentrations (µg/L) at each time point363
considered. The 5th, 50th and 95th percentiles of these distributions can be seen in364
Figure 8, with the observed data as dots. The two extreme percentiles reflect the365
uncertainty about the estimated concentrations.366
The plots show that some of the observations fall outside the percentiles. This is to367
be expected, as in theory approximately 10% of the data points should fall outside the368
limits given by the 90% credible interval. For the plasma concentrations, the uncertainty369
below the median seems to increase with time. This is not surprising given that less370
data were available at later time points as the concentrations of HEPS in some samples371
fell below the limit of detection. Further, the plot is on the log-scale, so these actually372
relate to very low concentrations.373
For the urine data, the upper bound of the 90% credible intervals extends noticably374
higher than the observed data. This suggests that BSV and/or MEV may be inflating375
estimates of FE leading to a larger than expected amount of HEPS being excreted376
renally. Thus, detection times may be longer than expected. Overall, both posterior377
predictive checks seem consistent with the observed data.378
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5.6 Withholding and detection times379
The detection time for a therapeutic substance represents the period after administra-380
tion that the laboratories can identify the substance or its metabolite in either blood381
or urine. The withholding time is usually judged by a veterinarian and represents382
the period between drug administration and a race, taking into account the published383
detection time and a number of other factors.384
Toutain (2010) used Monte Carlo methods to estimate withholding times by extrap-385
olating the detection times published by the European Horserace Scientific Liaison386
Committee. The methodology is based on the terminal phase or single exponential387
model for elimination, and also relies on estimating a plasma-to-urine concentration ra-388
tio parameter. An important feature of this research was the identification of the most389
influential parameters through a sensitivity analysis. This revealed that the manner in390
which the body processed the compound determines the detection time rather than, for391
example, dose.392
Given we have undertaken a full compartmental analysis under a Bayesian framework,393
we provide an alternative approach for the estimation of withholding times. This ap-394
proach will allow withholding times to be estimated from both plasma and urine sam-395
ples, and allows for the practical consideration that a horse will empty their bladder.396
5.6.1 Probability of detection in plasma397
Suppose we are interested in determining how likely it is for a horse to have a HEPS398
concentration in plasma greater than, say, the limit of detection (LOD) of 1 µg/L at399
a certain time t after being given an intravenous bolus dose of 30 mg of ACP. Given400
the population model developed in this research, this can be resolved by considering401
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the simulated data from the posterior predictive check. In the posterior predictive402
check, random samples are drawn from the posterior distribution of parameters and403
data generated for some time points (t). Thus, the probability of a horse having a404
HEPS concentration greater than, say, the LOD at time t can be determined from the405
simulated data. For a given time t, the number of simulated observations that are406
greater than the LOD is simply counted then divided by the total number of simulated407
observations at that particular time (t). This provides an estimate for the probability408
that a concentration will be larger than the LOD. A plot of these estimated probabilities409
can be seen in Figure 9.410
Figure 9 shows three plots. Figure 9a shows the estimated probabilities of detection411
based on the population estimates of parameters and therefore represents estimates for a412
typical horse in the sample. Alternatively, Figure 9b shows the estimated probabilities413
of detection for the individual horses in the study. The second plot shows how the414
probability of detection varies among individual horses. This highlights the potential415
for extreme detection probabilities for specific horses and the sensitivity of the estimates416
to the horses studied. The last plot is an empirical estimate of a survivor type function.417
The plot shows the estimates (with 95% confidence bounds) of the probability that418
a detection time is larger than some time t. For example, it shows that at 30 hours419
after acepromazine administration, while 10% of the horses would be expected to have420
a concentration of HEPS in plasma greater than the LOD, in practice this percentage421
may be as small as 0% or as large as 25%.422
5.6.2 Probability of detection in urine423
Assume we are interested in determining how likely it is for a horse to have a HEPS424
concentration in urine greater than, say, the LOD of 1 µg/L at a certain time (t) after425
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being given an intravenous bolus dose of 30 mg of ACP. The model for HEPS given in426
Section 4 predicts the accumulated urine amount of HEPS at a given time t. In order427
to determine detection times, an estimate of urine volume or accumulated urine volume428
at time t needs to be made.429
Figure 10 shows the observed cumulative urine volumes for all horses against time.430
A strong linear relationship is evident between cumulated volume and time, with the431
variability in the response increasing with time. Therefore, a linear mixed effects model432
with proportional residual error was fitted to the cumulative urine volume with time as433
the independent variable. Further details are given in Appendix A.434
It is now possible to predict the cumulative amount of HEPS and cumulative urine435
volume for a given time t. Given that detection in urine is based on concentration,436
these cumulative predictions need to be combined and converted to concentrations.437
One solution is to consider, say, 4 hour windows from the time of drug administration,438
and the amount of HEPS and urine volume accumulated in these windows can be used439
to predict concentration. This approach assumes the following.440
• The sample is representative of the population.441
• The model developed describes the population.442
• A linear relationship exists between urinary excretion rate of HEPS and the pro-443
duction rate of urine.444
• The urinary production and excretion rate on race day (and/or days before race445
day) are the same as production and excretion rates during the study.446
• The bladder is completely emptied at the beginning of each 4 hour interval.447
• Urine is collected at the end of a window.448
21
Data were simulated from the cumulative urine amount and volume models, and the449
probability of detection was estimated in the same way as plasma (described above).450
Results can be seen in Figure 11.451
Again, Figure 11 shows three plots. Figure 11a shows the estimated probability of452
detection in urine given a 4 hour window for a typical horse in the sample. The plot453
shows that there is quite a small probability of detection past 50 hours, for example.454
This agrees well with the observed and predicted data shown in Figure 8b as it appears455
that very little HEPS is accumulated in urine past this point in time. Figure 11b456
shows the estimated probabilities of detection based on individual estimates of PK457
parameters. These estimates relate to the individual horses in the study. The final plot458
shows an empirical estimate of a survivor type function. Detection times longer than459
70 hours appear rare given our best estimate. However, when calculating appropriate460
withholding times the uncertainty around this estimate should also be considered. Thus,461
while only 10% of horses might be expected to breech the detection level at 65 hrs, this462
estimate could be between 0 and 25% for an individual horse.463
6 Conclusion464
A Bayesian hierarchical model was considered for the description of the metabolism465
of the parent-metabolite process for ACP. Given the half-life of ACP is much smaller466
than the metabolite, the model was reducible to the consideration of the metabolite467
only. The structural form of this model for the description of metabolite concentration468
in plasma and cumulative amount in urine was based on mass balance with vague469
priors chosen for the estimable parameters. No covariates were found to be statistically470
significant. This may be attributed to the small sample of horses measured and/or471
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relatively narrow ranges of potential covariates, particularly for weight. Measurement472
variability on plasma concentrations proved to be influential, and random effects were473
included in the model to account for this.474
Simulation techniques were used to show agreement between predicted and observed475
data, and also in the estimation of detection times for a typical horse in the sample.476
Detection in urine was complicated by the need to allow the horses to empty their477
bladder at various times after ACP had been administered. This was resolved by478
considering urine concentration in 4 hour windows (post dose). Care should be take479
when interpreting these results as the probability profiles are likely to change if different480
sized windows are considered. Nevertheless, the results shown should provide guidance481
for trainers and veterinarians to estimate appropriate withholding times to ensure that482
horses are not racing with prohibited substances in their system.483
All inferences in this paper were based on a sample of twelve horses. In making de-484
cisions in the model-building phase and providing estimate of, for example, clearance485
and withholding times, we assume that this sample is representative of the entire pop-486
ulation. Indeed, in the selection of covariates, weight seemed somewhat linearly related487
to volume of distribution. This relationship did not prove to be statistically significant,488
but this may have been due to the small sample size. Hence, care should be taken when489
drawing any inferences from this work.490
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A Model for cumulative urine volume496
The individual fits can be seen in Figure A.1. From the plot, the proposed model seems497
to fit the observed data well for all horses.498
The residual plots and posterior predictive check can be seen in Figures A.2 and A.3,499
respectively. The posterior predictive check also shows the 90% credible interval for500
the predicted response. The QQ-plot, histogram and observed vs. predicted plots show501
that the residuals generally follow a Normal distribution. There is a slight pattern502
in the residual vs. predicted plot, but this was not deemed strong enough to violate503
our assumption about the residuals. The posterior predictive check shows agreement504
between the simulated and observed data, and also shows that some observations lie505
outside the 90% credible interval.506
507
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Glossary of terms508
ACP Acepromazine
BHM Bayesian hierarchical model
BSV Between subject variability
Cl/FPM Clearance (scaled by fraction of parent converted to metabolite)
CLNR Clearance non-renal
CLR Clearance renal
D¯ Expectation of deviance
D Dose
DIC Deviance information criterion
f(.) Predicted response
FE Fraction excreted renally
FEM Fraction of metabolite excreted renally
FEP Fraction of parent excreted renally
FPM Fraction of parent converted to metabolite
HEPS 2-(1-hydroxyethyl)promazine
k Rate constants
LOD Limit of detection
LOQ Limit of quantification
M Metabolite
MCMC Markov chain Monte Carlo
MEV Measurement error variability
MVN Multivariate normal distribution
ODE Ordinary differential equation
509
510
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P Parent
pD Effective number of parameters
PK Pharmacokinetic
SD Standard deviation
t Time
Uni Uniform distribution
w Weight (kg)
W Wishart distribution
Z Covariate values
V/FPM Volume of distribution (scaled by fraction of parent converted to metabolite)
Φ Variability of model parameters due to measurement error
Ω Between subject variability
θ Individual model parameter values
θ¯ Expectation of parameter values
µ Typical model parameter values
β Covariate model parameters
σ2add Additive residual variance
σ2prop Proportional residual variance
511
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Figure 1: Parent-metabolite model for acepromazine (P ) and 2-(1-
hydroxyethyl)promazine (M) in horses.
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horses.
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Figure 4: Plots of posterior means of individual parameter estimates vs. covariates.
565
33
0 5 10 15 20 25
0
2
Horse 1
Time (hrs)
lo
g 
Co
nc
 (µ
g/
L)
0 5 10 15 20 25
−1
0
1
2
Horse 2
Time (hrs)
lo
g 
Co
nc
 (µ
g/
L)
0 5 10 15 20 25
−2
−1
0
1
2
Horse 3
Time (hrs)
lo
g 
Co
nc
 (µ
g/
L)
0 5 10 15 20 25
−2
−1
0
1
2
Horse 4
Time (hrs)
lo
g 
Co
nc
 (µ
g/
L)
0 5 10 15 20 25
−1
0
1
2
Horse 5
Time (hrs)
lo
g 
Co
nc
 (µ
g/
L)
0 5 10 15 20 25
−2
−1
0
1
2
Horse 6
Time (hrs)
lo
g 
Co
nc
 (µ
g/
L)
0 5 10 15 20 25
−1
0
1
2
Horse 7
Time (hrs)
lo
g 
Co
nc
 (µ
g/
L)
0 5 10 15 20 25
−2
−1
0
1
2
Horse 8
Time (hrs)
lo
g 
Co
nc
 (µ
g/
L)
0 5 10 15 20 25
−2
−1
0
1
2
Horse 9
Time (hrs)
lo
g 
Co
nc
 (µ
g/
L)
0 5 10 15 20 25
−2
−1
0
1
2
Horse 10
Time (hrs)
lo
g 
Co
nc
 (µ
g/
L)
0 5 10 15 20 25
−2
−1
0
1
2
Horse 11
Time (hrs)
lo
g 
Co
nc
 (µ
g/
L)
0 5 10 15 20 25
−2
−1
0
1
2
Horse 12
Time (hrs)
lo
g 
Co
nc
 (µ
g/
L)
Figure 5: Individual fitted values for plasma concentrations of HEPS. The dashed and
solid lines (-, - -) represent the duplicate measurements on the same blood sample which
the dots represent the observed data points.
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Figure 6: Individual fitted values for cumulative urine amounts of HEPS. The solid
lines represent the predicted values and the dots represent the observed data points.
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bottom row refers to cumulative urine amount (µg)) including standardized residuals
vs. predicted values, Normal QQ-plot of the standardized residuals, histogram of the
standardized residuals and observed vs. predicted values.
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Figure 8: Posterior predictive check for plasma concentrations and urine amounts of the
acepromazine metabolite HEPS in 12 horses. The dots represent actual observations.
The solid line represents the model and the dashed lines represent a 90% credible
interval for the model predictions.
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Figure 9: Probability plots for the detection of the acepromazine metabolite HEPS in
plasma after the intravenous administration of 30 mg of acepromazine; (a) Population
estimate of the probability of detection, (b) Individual horse estimate of the probability
of detection and (c) Estimated survivor type function for detection times.
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Figure 10: Observed cumulative urine volumes against time.
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Figure 11: Probability plots for the detection of the acepromazine metabolite HEPS in
urine after the intravenous administration of 30 mg of acepromazine based on 4 hour
windows; (a) Population estimate of the probability of detection, (b) Individual horse
estimate of the probability of detection and (c) Estimated survivor type function for
detection times.
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Figure A.1: Individual fits for cumulative urine volume model.
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Figure A.2: Residual plots for cumulative urine volume model.
574
42
0 10 20 30 40 50 60
0
0.5
1
1.5
2
2.5
3
x 104
Time (hrs)
Cu
m
. V
. (m
L)
Figure A.3: Posterior predictive check for cumulative urine volume model where ‘Cum.
V’ represents the cumulative amount of urine collected from the 12 horses over the
duration of the study.
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Table 1: Summary of horses analysed.
Horse Median Weight (kg) Age (yrs) Sex Breed Dose (mg/kg)
1 570 11 Gelding Thoroughbred 0.053
2 540 15 Gelding Thoroughbred 0.056
3 670 10 Gelding Thoroughbred 0.045
4 544 9 Gelding Standardbred 0.055
5 550 8 Gelding Thoroughbred 0.055
6 574 9 Gelding Standardbred 0.052
7 538 7 Gelding Standardbred 0.056
8 566 8 Gelding Standardbred 0.053
9 478 4 Gelding Standardbred 0.063
10 552 5 Gelding Standardbred 0.054
11 474 7 Gelding Standardbred 0.063
12 560 9 Gelding Standardbred 0.054
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Table 2: Median deviance and 95% credible interval of deviance.
Model Res. plasma Res. urine Median deviance 95% CI for deviance
Figure 2 Add. Add. 2115 (2100, 2137)
Figure 2 Prop. Prop. 2212 (2197, 2233)
Figure 2 Add. Prop. 2312 (2296, 2334)
Figure 2 Prop. Add. 2049 (2034, 2069)
Figure 2 Mix. Mix. 2120 (2104, 2148)
Figure 2 + MEV Prop. Add. 1977 (1951, 2007)
Figure 2 + MEV + wt-V Prop. Add. 1977 (1951, 2008)
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Table 3: Summary of parameter estimates (posterior medians) for final model.
Parameter Cl/FPM (L/hr) FE V/FPM (L) k12 σprop,1 σadd,2
Estimate 769 0.0856 6874 35.87 0.16 109
BSV (%) 0.09 (30%) 0.11 (32%) 0.07 (27%) - - -
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